Cercacor Laboratories, Inc. v. Metronom Health, Inc.

CourtSuperior Court of Delaware
DecidedApril 23, 2025
DocketN23C-05-200 PRW CCLD
StatusPublished

This text of Cercacor Laboratories, Inc. v. Metronom Health, Inc. (Cercacor Laboratories, Inc. v. Metronom Health, Inc.) is published on Counsel Stack Legal Research, covering Superior Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cercacor Laboratories, Inc. v. Metronom Health, Inc., (Del. Ct. App. 2025).

Opinion

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE

CERCACOR LABORATORIES, INC., ) ) Plaintiff, ) ) v. ) C.A. No. N23C-05-200 PRW ) CCLD METRONOM HEALTH, INC., and ) OLAV BERGHEIM, ) ) Defendants. )

Submitted: March 14, 2025 Decided: April 22, 2025

Upon Defendants’ Motion for Summary Judgment, DENIED, in part; GRANTED, in part.

Upon Plaintiff ’s Partial Motion for Summary Judgment Regarding Defendants’ Counterclaims, DENIED, in part; GRANTED, in part.

MEMORANDUM OPINION AND ORDER

J. Clayton Athey, Esquire, Eric J. Juray, Esquire, Christine N. Chappelear, Esquire, and Kristen M. Valania, Esquire, PRICKETT, JONES & ELLIOTT, P.A., Wilmington, Delaware; Christopher M. Francis, Esquire (argued), Mark T. Palin, Esquire, and Brian M. Wheeler, Esquire, ATKINSON, ANDELSON, LOYA, RUUD & ROMO P.C., Pasadena, California, Attorneys for Plaintiff Cercacor Laboratories, Inc.

Marc S. Casarino, Esquire, and Katie Barksdale, Esquire, KENNEDYS CMK LLP, Wilmington, Delaware; Theresa A. Kristovich, Esquire (argued), and Tyler S. Dobberstein, Esquire, KABAT CHAPMAN & OZMER LLP, Los Angeles, California, Attorneys for Defendants Metronom Health, Inc., and Olav Bergheim.

WALLACE, J. This case arises out of Plaintiff Cercacor Laboratories, Inc.’s, proposed

acquisition of Defendant Metronom Health, Inc. (the “Proposed Transaction”).1 To

work towards finalizing the Proposed Transaction, the parties signed a binding Letter

of Intent (the “LOI”).2 Defendant Olav Bergheim signed the LOI on Metronom’s

behalf as the company’s CEO.3 When the parties executed the LOI, Metronom was

in dire financial straits.4 Accordingly, Cercacor agreed to provide Metronom with

weekly cash infusions while negotiating the Proposed Transaction.5

But negotiations didn’t go entirely to plan. According to Cercacor, Metronom

“delayed in providing key [due diligence] information, refused to allow [] access to

its personnel, and failed to contract its debtholders to provide notice of the

transaction and obtain [debt] releases as it had agreed to do.”6 While Metronom

says Cercacor postponed sending a draft Asset Purchase Agreement and the draft

that was finally provided contained substantial inaccuracies and other issues.7 All

1 See Complaint (hereafter “Compl.”) ¶¶ 1-4 (D.I. 1). 2 See generally Compl., Ex. A (hereafter “LOI”) (D.I. 1). 3 Id. at 5. 4 Plaintiff’s Opening Brief in Support of its Motion for Partial Summary Judgment (hereafter “PMSJ”), Ex. 2 (“Beach Rebuttal Report”) ¶ 20 (D.I. 91) (“Metronom was not a ‘going concern’ and it faced imminent financial collapse.”). 5 LOI § 8. 6 PMSJ at 9 (citing PMSJ, Ex. 4 (“Bergheim Dep.”) at 167-68; Ex. 5 (“Wade Dep.”) at 77-78; Ex. 20 (“Wade Email”); Ex. 21 (“Kang Dep.”) at 88-90). 7 Opening Brief in Support of Defendants’ Motion for Summary Judgment (hereafter “DMSJ”) at 8 (D.I. 94) (citing Declaration of Michael Sanders to Motion for Summary Judgment (hereafter “Sanders Dec.”) ¶ 16; Saunders Dec., Ex. 14 (hereafter “Draft APA”).

-1- that said, Metronom maintains the parties were “really, really close” to a final

agreement8 when Cercacor terminated the LOI.9

Before the Court are the parties’ Cross-Motions for Summary Judgment.

Cercacor seeks to knock out Metronom’s two Counterclaims.10 Defendants ask the

Court to enter judgment as a matter of law in their favor on all Cercacor’s claims.11

For the reasons now explained, the Court partially GRANTS each motion and

partially DENIES each.

I. FACTUAL AND PROCEDURAL BACKGROUND

A. THE PARTIES AND THE LOI’S NEGOTIATION

Plaintiff Cercacor is a Delaware corporation based in Irvine, California, that

develops health and fitness technology, including a continuous glucose monitoring

(“CGM”) device.12

Defendant Metronom is a Delaware corporation with its principal place of

business in Laguna Hills, California.13 Defendant Bergheim is Metronom’s CEO.14

8 Id. at 12, 16, 26, 28-29 (quoting Declaration of Theresa Kristovich to Motion for Summary Judgment (hereafter “Kristovich Dec.”), Ex. 3 (“Hammarth Dep.”) at 252-55). 9 See Compl. ¶ 37. 10 See DMSJ; see also Defendants’ Answer to Plaintiff’s Complaint and Metronom’s Counterclaims Against Cercacor (hereafter “Answer”) at 51-54 (D.I. 34). 11 See PMSJ; see also Compl. ¶¶ 38-86. 12 See Compl. ¶ 5; Kristovich Dec., Ex. 6 (“Vo Dep.”) at 24, 41. 13 See Compl. ¶ 6. 14 See id. ¶ 7; PMSJ, Bergheim Dep. at 50.

-2- During the relevant period, Metronom was a pre-revenue medical device company

focused on developing a CGM.15

As a development-stage company, Metronom had no revenue and depended

on investor funds to pay its operating expenses.16 By early 2023, that funding had

dried-up, and Metronom expected to close if it didn’t find an acquisition partner.17

Metronom discussed a possible sale of its business with several potential acquisition

partners.18 After these discussion fell through, and Metronom began “moving

forward to close its operations . . . and cease doing business.”19

While Metronom explored winding down its business, Defendants held two

meetings with Cercacor to discuss the Potential Transaction.20 The first meeting

discussed Metronom’s “dire financial straits.”21 The parties met again on March 30,

2023, the eve of Metronom shutting its doors.22 After that all-day meeting, the

15 Sanders Dec. ¶¶ 2-3; PMSJ, Ex. 1 (“Hammarth Dep.”) at 58; Kristovich Dec., Ex. 2 (“Wade Dep.”) at 88-89. 16 See Beach Rebuttal Report (“Metronom’s balance sheet showed that it owed over $33.2 million in liabilities, $29.8 million of which consisted of loans as of February 29, 2023. Other liabilities included approximately $0.4 million of accounts payable, $1.7 million of accrued interest, and $0.4 million of accrued payroll and other employee costs.”); Ex. 3 (Metronom’s balance sheet showing substantial expenses and no revenue); Wade Dep. at 53-54. 17 Sanders Dec. ¶ 2. 18 Id. at ¶ 3; Wade Dep. at 54-55; Kristovich Dec., Ex. 5 (“Muhsin Dep.”) at 20, 25-26. 19 Sanders Dec. ¶ 3. 20 Muhsin Dep. at 37, 39-40. 21 Id. at 39. 22 Sanders Dec. ¶ 4; Bergheim Dep. at 107; Wade Dep. at 33, 40-41.

-3- parties signed the LOI.23

B. THE LOI

Several LOI provisions are relevant to the parties’ dispute. Section 1 states

the LOI’s purpose is to facilitate the Potential Transaction—by which Cercacor

“would purchase [Metronom] (or the assets thereof) on a cash free, debt free . . .

basis for a total consideration of 100,000 shares of [Cercacor’s] common stock.”24

While the LOI didn’t explicitly require Metronom to secure releases from its

debtholders, during negotiations Mr. Bergheim told the Metronom board that “[w]e

will need other debt holders to release their debt.”25

The LOI conditioned Cercacor’s proposal on “the satisfactory completion . . .

of business, tax, accounting and legal due diligence,” as well as “the negotiation and

execution of a definitive transaction agreement.”26 The LOI obligated the parties to

“use good faith efforts to negotiate the Definitive Agreement . . . as promptly as

practicable.”27 While the parties negotiated a Definitive Agreement, Metronom

agreed to “operate its business in the ordinary course consistent with past practice.”28

To prevent Metronom from closing while the parties negotiated, Cercacor

23 Sanders Dec. ¶¶ 4-12 (detailing the parties’ LOI negotiations). 24 LOI § 1. 25 PMSJ, Ex. 11 (Email from Bergheim to Board of Directors). 26 LOI § 2. 27 Id. 28 Id. § 3.

-4- agreed to pay Metronom’s “operating expenses.”29 And Cercacor made all required

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sune Lyxell v. John B. Vautrin
604 F.2d 18 (Fifth Circuit, 1979)
In Re Wheelabrator Technologies, Inc. Shareholders Litigation
663 A.2d 1194 (Court of Chancery of Delaware, 1995)
Moore v. Sizemore
405 A.2d 679 (Supreme Court of Delaware, 1979)
Dunlap v. State Farm Fire & Casualty Co.
878 A.2d 434 (Supreme Court of Delaware, 2005)
Goodrich v. E.F. Hutton Group, Inc.
542 A.2d 1200 (Court of Chancery of Delaware, 1988)
Arnold v. Society for Sayings Bancorp, Inc.
678 A.2d 533 (Supreme Court of Delaware, 1996)
Sears, Roebuck & Co. v. Hsu-Nan Huang
652 A.2d 568 (Supreme Court of Delaware, 1995)
Telxon Corporation v. Meyerson
802 A.2d 257 (Supreme Court of Delaware, 2002)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
Kuroda v. SPJS Holdings, L.L.C.
971 A.2d 872 (Court of Chancery of Delaware, 2009)
Lipson v. Anesthesia Services, P.A.
790 A.2d 1261 (Superior Court of Delaware, 2001)
Allied Capital Corp. v. GC-Sun Holdings, L.P.
910 A.2d 1020 (Court of Chancery of Delaware, 2006)
Lord v. Souder
748 A.2d 393 (Supreme Court of Delaware, 2000)
DeBonaventura v. Nationwide Mutual Insurance Co.
419 A.2d 942 (Court of Chancery of Delaware, 1980)
Judah v. Delaware Trust Co.
378 A.2d 624 (Supreme Court of Delaware, 1977)
Schock v. Nash
732 A.2d 217 (Supreme Court of Delaware, 1999)
Aspen Advisors LLC v. United Artists Theatre Co.
861 A.2d 1251 (Supreme Court of Delaware, 2004)
Allen v. El Paso Pipeline GP Company, L.L.C.
113 A.3d 167 (Court of Chancery of Delaware, 2014)
Nationwide Emerging Managers, LLC v. Northpointe Holdings, LLC
112 A.3d 878 (Supreme Court of Delaware, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Cercacor Laboratories, Inc. v. Metronom Health, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/cercacor-laboratories-inc-v-metronom-health-inc-delsuperct-2025.